{"id":"androgel-1-62","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions (erythema, pruritus)"},{"rate":null,"effect":"Acne"},{"rate":null,"effect":"Polycythemia"},{"rate":null,"effect":"Gynecomastia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:51:57.944309","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug delivers testosterone transdermally through a gel formulation applied to the skin, where it is absorbed into the systemic circulation. Testosterone binds to androgen receptors throughout the body to restore normal male sexual function, muscle mass, bone density, and other androgen-dependent physiological processes in men with clinically low testosterone.","oneSentence":"AndroGel 1.62% is a testosterone replacement therapy that restores physiological testosterone levels in hypogonadal men.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:27.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone replacement therapy in adult males with hypogonadism"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT06084338","phase":"PHASE2","title":"Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-12-14","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT03887936","phase":"PHASE4","title":"Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-10-01","conditions":"Type 2 Diabetes Mellitus, Hypogonadism","enrollment":92},{"nctId":"NCT02432261","phase":"PHASE1","title":"Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men","status":"COMPLETED","sponsor":"Kimberly Myer","startDate":"2015-04","conditions":"Healthy","enrollment":44},{"nctId":"NCT03518034","phase":"PHASE4","title":"A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-03","conditions":"Hypogonadism, Cardiovascular Diseases","enrollment":5246},{"nctId":"NCT05825092","phase":"PHASE2","title":"Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2023-07-21","conditions":"Critical Illness","enrollment":600},{"nctId":"NCT03198728","phase":"PHASE3","title":"Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men","status":"COMPLETED","sponsor":"Marius Pharmaceuticals","startDate":"2017-07-05","conditions":"Hypogonadism, Male","enrollment":314},{"nctId":"NCT03678233","phase":"PHASE2","title":"Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2019-06-27","conditions":"Hypermetabolism in ICU, Loss of Muscle Mass, Functional Disability After ICU","enrollment":30},{"nctId":"NCT04274894","phase":"PHASE4","title":"A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-05-12","conditions":"Hypogonadism","enrollment":246},{"nctId":"NCT01686828","phase":"PHASE1, PHASE2","title":"T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin","status":"COMPLETED","sponsor":"University of Washington","startDate":"2013-06","conditions":"Insulin Resistance, Type 2 Diabetes Mellitus, Obesity","enrollment":53},{"nctId":"NCT02081300","phase":"PHASE3","title":"Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2014-02","conditions":"Male Hypogonadism","enrollment":315},{"nctId":"NCT02317640","phase":"PHASE1, PHASE2","title":"TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2017-03-15","conditions":"Spinal Cord Injury","enrollment":56},{"nctId":"NCT01940718","phase":"EARLY_PHASE1","title":"Androgen Regulation of Priapism in Sickle Cell Disease","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2014-03","conditions":"Priapism, Sickle Cell Disease, Hypogonadism","enrollment":""},{"nctId":"NCT01993225","phase":"PHASE3","title":"A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2014-01","conditions":"Secondary Hypogonadism","enrollment":120},{"nctId":"NCT01993212","phase":"PHASE3","title":"A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%","status":"COMPLETED","sponsor":"Repros Therapeutics Inc.","startDate":"2014-01","conditions":"Secondary Hypogonadism","enrollment":120},{"nctId":"NCT02110368","phase":"PHASE3","title":"Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2014-03","conditions":"Primary Hypogonadism, Hypogonadotropic Hypogonadism","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2006","pmid":"30000781","title":"Testosterone.","journal":""}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Testosterone gel"],"phase":"marketed","status":"active","brandName":"AndroGel 1.62%","genericName":"AndroGel 1.62%","companyName":"Repros Therapeutics Inc.","companyId":"repros-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AndroGel 1.62% is a small molecule testosterone gel used to treat conditions such as hypogonadism and loss of muscle mass. It is applied topically using a pump.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}